The incidence of lung cancer is the highest among all tumors, and treatment has become an urgent problem to be solved. The Drug-eluting bead-based bronchial arterial chemoembolization (DEB-BACE) combination immunotherapy is a rare neoadjuvant therapy for lung cancer surgery, which can significantly reduce the time it takes for lung cancer patients to undergo surgery.We report a male patient, aged 59-year-old, with Stage-III b squamous cell lung cancer accompanied by hemoptysis underwent surgical resection after DEB-BACE combination immunotherapy treatment 21 days later without obvious adverse events. A pathologic complete response (pCR) was observed postoperatively, and the patient has made a successful recovery. The DEB-BACE combined with immunotherapy might be a new neoadjuvant therapy option for locally advanced non-small cell lung.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668917PMC
http://dx.doi.org/10.2147/IMCRJ.S491862DOI Listing

Publication Analysis

Top Keywords

lung cancer
20
cell lung
12
bronchial arterial
8
arterial chemoembolization
8
combined immunotherapy
8
complete response
8
squamous cell
8
deb-bace combination
8
combination immunotherapy
8
neoadjuvant therapy
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!